Related Experiment Video
Updated: May 22, 2026
09:11
Assays for Validating Histone Acetyltransferase Inhibitors
Published on: August 6, 2020
Abstract:
One agent reduces tamoxifen resistance in preclinical studies, while lysine acetylation measurements may monitor clinical benefit of a second drug.
Insights
A novel agent shows promise in overcoming tamoxifen resistance in preclinical models. Additionally, lysine acetylation levels may serve as a biomarker to track the effectiveness of another therapeutic agent in clinical settings.
Area of Science:
- Oncology
- Pharmacology
- Biochemistry
Background:
- Tamoxifen resistance is a significant clinical challenge in estrogen receptor-positive breast cancer treatment.
- Developing strategies to overcome tamoxifen resistance is crucial for improving patient outcomes.
Discussion:
- Preclinical studies indicate that a specific agent can effectively reduce tamoxifen resistance.
- Lysine acetylation is explored as a potential biomarker for monitoring treatment response.
Key Insights:
- The identified agent demonstrates potential in preclinical settings to reverse or mitigate tamoxifen resistance.
- Lysine acetylation patterns correlate with the clinical efficacy of a separate therapeutic agent, suggesting its utility in treatment monitoring.
Outlook:
- Further investigation into the mechanism of action of the resistance-reducing agent is warranted.
- Clinical validation of lysine acetylation as a predictive or monitoring biomarker is a key future direction.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...